Simborio Hannah Leah Tadeja, Reyes Alisha Wehdnesday Bernardo, Hop Huynh Tan, Arayan Lauren Togonon, Min Wongi, Lee Hu Jang, Lee Jin Ju, Chang Hong Hee, Kim Suk
Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Republic of Korea.
Animal and Plant Quarantine Agency, Anyang 14089, Republic of Korea.
J Microbiol Biotechnol. 2016 Mar;26(3):603-9. doi: 10.4014/jmb.1509.09061.
Brucellosis affects a wide range of host species, including humans and many livestock animals. Chronic infections of the disease make antibiotic treatment costly, and the current vaccine used in livestock has not been approved for human use. This study investigated the possible use of the Brucella abortus outer membrane protein A (OmpA) as a candidate subunit vaccine in an infected mouse model. The ompA gene was cloned and overexpressed, and the recombinant OmpA (rOmpA) protein fused to maltose binding protein (MBP) was purified in Escherichia coli. Immunogenicity was verified through western blotting, and mice were immunized and challenged to evaluate its protective effect. Mice treated with rOmpA exhibited induced humoral and host cell-mediated responses, with a significant increase in immunoglobulin G (IgG1 and IgG2a) and cytokine levels, especially TNF-α and IL-12, compared with the control groups treated with either MBP or PBS. In conclusion, rOmpA should be highly considered as a future subunit vaccine for brucellosis, and further studies regarding rOmpA and its protective ability are suggested.
布鲁氏菌病会影响包括人类和许多家畜在内的多种宿主物种。该疾病的慢性感染使得抗生素治疗成本高昂，并且目前用于家畜的疫苗尚未获批用于人类。本研究在感染小鼠模型中调查了布鲁氏菌流产亚种外膜蛋白A（OmpA）作为候选亚单位疫苗的可能性。克隆并过表达了ompA基因，在大肠杆菌中纯化了与麦芽糖结合蛋白（MBP）融合的重组OmpA（rOmpA）蛋白。通过蛋白质印迹法验证免疫原性，并对小鼠进行免疫和攻毒以评估其保护效果。与用MBP或PBS处理的对照组相比，用rOmpA处理的小鼠表现出诱导的体液和宿主细胞介导的反应，免疫球蛋白G（IgG1和IgG2a）和细胞因子水平显著增加，尤其是肿瘤坏死因子-α和白细胞介素-12。总之，rOmpA应被高度视为未来用于布鲁氏菌病的亚单位疫苗，建议对rOmpA及其保护能力进行进一步研究。
